What Gala Therapeutics does

Gala Therapeutics, now operating as Galvanize Therapeutics, Inc. following the 2022 merger of Gala Therapeutics and Galaxy Medical, is a privately-held medical device company developing pulsed electric field (PEF) energy systems for the surgical ablation of soft tissue. The company's flagship Aliya PEF platform delivers non-thermal energy that engages the body's molecular machinery to eliminate target cells through regulated cell death mechanisms, a fundamentally different mechanism from conventional thermal or radiofrequency ablation. Its product portfolio includes the FDA-cleared Aliya EX Generator (cleared May 2026, offering 2x the diameter and up to 7x the treatment volume of prior generation), the broader Aliya PEF system for interventional pulmonology and thoracic oncology, and the RheOx bronchial rheoplasty system targeting airway and COPD conditions. The company is headquartered at 3200 Bridge Parkway, Redwood City, California.

Galvanize targets three primary customer segments: interventional pulmonologists performing bronchoscopy and therapeutic bronchoscopy, thoracic oncologists and surgeons treating lung tumors and metastatic cancers, and pulmonologists treating COPD and airway disease. The company sells to hospitals and healthcare systems through a direct enterprise field sales organization, led by a Chief Commercial Officer and a Senior Vice President of Sales and Marketing, with additional VPs covering global market development and business development.

The business model is a classic medical device capital equipment and consumables motion: hospital systems purchase or lease Aliya PEF generators and procure associated disposable ablation catheters and accessories for each procedure. Pricing is quote-based and negotiated through institutional purchasing agreements rather than publicly disclosed. The company is backed by life sciences venture firms ATP (Apple Tree Partners, the founding investor that created both predecessor companies in 2015 and 2020) and Sofinnova Partners, with founder Jonathan Waldstreicher continuing as Founder of the combined entity. As of the May 2026 FDA clearance of the Aliya EX Generator, the company is positioned at the commercial launch inflection point for its core platform.

Name

Gala Therapeutics

Legal name

Galvanize Therapeutics, Inc.

Website

https://galatherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Gala Therapeutics (now Galvanize Therapeutics) is a privately-held medical device company that develops Aliya pulsed electric field ablation systems for surgical treatment of soft tissue, targeting interventional pulmonologists, thoracic oncologists, and hospitals performing lung tumor and COPD procedures.

Ownership category

akta.pro rank

Product category

Surgical Ablation Devices (Interventional Pulmonology and Thoracic Oncology)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Pulsed electric field ablation
• Surgical ablation devices
• Interventional pulmonology devices
• Thoracic oncology devices
• Soft tissue ablation

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Medical Device Hardware Sales: Sale of FDA-cleared surgical ablation devices including Aliya EX Generator and related disposable products for pulsed electric field ablation procedures

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Gala Therapeutics (now operating as Galvanize Therapeutics) develops and commercializes FDA-cleared medical devices based on its proprietary Aliya Pulsed Electric Field (PEF) energy platform for surgical ablation of soft tissue. The portfolio includes the Aliya EX Generator for lung tumor and metastatic cancer ablation, and the RheOx bronchoscopic system for airway and COPD treatment. Devices are sold to hospitals, health systems, and specialty physicians in interventional pulmonology and thoracic oncology.

Product overview

Galvanize Therapeutics offers a unified portfolio of medical devices centered on its proprietary Aliya Pulsed Electric Field (PEF) energy platform. The flagship Aliya PEF system provides surgical ablation of soft tissue through regulated cell death mechanisms. The company recently expanded its portfolio with the FDA-cleared Aliya EX Generator, which delivers 2x the diameter for up to 7x the treatment volume. Additionally, the RheOx bronchoscopic system addresses airway and COPD conditions. The platform emphasizes safety, predictability, clinical compatibility, and immune potential as key differentiators.

Differentiator

Problem solved

Functional benefit

Brands

• Aliya: Proprietary Pulsed Electric Field (PEF) energy platform for surgical ablation of soft tissue, including the Aliya EX Generator and Aliya PEF system.
• Aliya PEF
• Aliya EX
• RheOx
• Aliya PEF Clinical Community Forum

Products and services

• Aliya PEF (Pulsed Electric Field) Platform A proprietary pulsed electric field energy platform that engages the body's molecular machinery to eliminate cells in a controlled manner using regulated cell death mechanisms; designed for surgical ablation of soft tissue and used by interventional pulmonologists, thoracic oncologists, and hospitals.
• Aliya EX Generator FDA-cleared next-generation PEF ablation energy generator offering 2x the diameter for up to 7x the treatment volume with safety, predictability, clinical compatibility, and immune potential features; sold to hospitals and health systems for interventional pulmonology and thoracic oncology procedures.
• RheOx Bronchoscopic valve and therapeutic intervention system for the treatment of airway and chronic obstructive pulmonary disease (COPD), part of the airway/COPD division within the broader Aliya platform; used by interventional pulmonologists and COPD specialists.

Quantifiable outcome

• FDA clearance received May 18, 2026 for Aliya EX Generator
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Global medtech incumbent with established ablation franchises (including cryoablation and microwave ablation) used in cardiac, pulmonary, and oncology procedures. Directly relevant as the largest hospital-channel competitor to Galvanize's PEF ablation platform.
• Boston Scientific: Major interventional medtech company with RF ablation and pulmonary/cancer therapy products. Competes for the same hospital capital and procedural budgets as Galvanize, particularly in thoracic oncology.
• Johnson & Johnson (Biosense Webster): Acquired Shockwave Medical for $13.1B and Auris Health for $3.4B, both reference points for Galvanize's leadership. J&J's interventional and surgical oncology portfolios position it as a strategic acquirer and direct competitive threat in ablation.
• Olympus Corporation: Dominant player in bronchoscopy and interventional pulmonology (per CCO Gabe McHugh's prior leadership of the $2.2B Surgical & Interventional Solutions Division). Competes at the procedural level for interventional pulmonology procedures.
• Stryker: Diversified medtech with surgical, ENT, and oncology ablation offerings. Relevant as both a competitor in surgical ablation and as a reference strategic acquirer (acquired Vocera, led by Galvanize's CFO Steve Anheier).

Direct peers

• AngioDynamics: Specialized medical device company with a portfolio of thermal and non-thermal ablation technologies (including NanoKnife irreversible electroporation) used in soft tissue and oncology applications. Closest direct peer in modality overlap with Galvanize's PEF.
• AtriCure: Commercial-stage medical device company focused on surgical ablation technologies, including pulsed field ablation in cardiac indications. Highly relevant peer given overlapping PEF/surgical ablation modality and similar enterprise hospital sales model.
• Shockwave Medical (J&J): Reference comparable for Galvanize's strategic trajectory: developed and commercialized a novel energy-based intervention (intravascular lithotripsy) led by the same CEO (Doug Godshall) and grew to a $13.1B J&J acquisition. Closest analog in business model, modality differentiation, and exit profile.

Emerging players

• HistoSonics: Emerging non-invasive histotripsy ablation company developing a fundamentally different energy modality for soft tissue ablation. Comparable emerging modality-based ablation competitor with similar commercial-stage profile.
• Penumbra: Vascular thrombectomy and emerging interventional therapy company that has expanded into adjacent oncology and pulmonary applications. Comparable mid-stage medtech with similar growth-stage and capital-equipment-plus-disposable model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/galvanize-therapeutics
• Xx.com/GalaTherapeuti1

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gala Therapeutics